ACTRN12614000812695终止2 期
The effect of mesenchymal stem cell injections following arthroscopic microfracture versus microfracture alone on cartilage healing in patients with an isolated knee cartilage defect.
Magellan Stem Cells0 个研究点目标入组 40 人开始时间: 2014年7月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 50 Years(—)
- 性别
- All
入选标准
- •1.Aged between 18 – 50 (inclusive). As isolated full thickness chondral defects are often traumatic in nature it is likely that this age restriction represents the majority of patients who undergo microfracture.
- •2.Pre-operative radiological diagnosis of an isolated full thickness knee cartilage defect of the medial or lateral femoral condyle
- •3.Planned arthroscopic microfracture/osteoplasty
- •4.Sufficient English skills to complete the questionnaires required for the study, as well as to understand the instructions given by the study doctors.
- •5.No plans at the time of enrolment to undergo surgery in the following three months. This criterion is aimed at avoiding co-interventions that may confound the results of the study. While involvement in the project will not strictly prevent participants from undertaking such interventions if required, we will exclude volunteers who already have such procedures scheduled
排除标准
- •1.Pregnancy (accepted contra-indication as no safety data on this population).
- •2.Have other causes of their knee symptoms suspected to be due to serious pathology such as tumour or referral from the hip or lumbar spine. These conditions are not under investigation within the current project;
- •3.Blood disorder (accepted contra-indication as no safety data on this population)
- •4.MRI confirmed displaced meniscial tear.
- •5.MRI confirmed Grade II-IV degenerative osteoarthritis
- •6.History of cancer
- •7.History of atypical chronic pain syndrome
研究者
相似试验
进行中(未招募)
1 期
Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress SyndromeModerate to severe SARS-Cov-2 related acute respiratory distress syndromeMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-002772-12-FRCHRU NANCY30
已完成
1 期
Evaluation of Mesenchymal stem cell therapy effects on the cellular immune response in refractory rheumatoid arthritis patientsRheumatoid arthritis.Diseases of the musculoskeletal system and connective tissueIRCT2015102824760N1Research Chancellor, Mashhad University of Medical Sciences21
招募中
3 期
Mesenchymal stem cells derived from the placenta and its secretions in the treatment of graft versus host diseaseGraft-versus-host diseaseGraft versus host disease.D89.81IRCT20201108049311N7Tabriz University of Medical Sciences30
已完成
不适用
Effects of cell therapy with mesenchymal stem cells and platelet-rich plasma in the treatment of knee osteoarthritisOsteoarthritis, KneeRBR-2fr526nniversidade Federal de Mato Grosso do Sul
已完成
不适用
Effects of mesenchymal stem cells therapy in peritoneal dialysis patientsChronic kidney disease.Chronic kidney disease, stage 5IRCT2015052415841N2Vice chancellor for research, Tehran University of Medical Sciences10
